Types of Cancers Prevailing in Pakistan and their Management Evaluation

  • Tariq, Ayesha (Faculty of Pharmacy, University of Central Punjab) ;
  • Majeed, Imtiaz (Faculty of Pharmacy, University of Central Punjab) ;
  • Khurshid, Azhar (Shoakat Khanum Memorial Cancer Hospital and Research Centre)
  • Published : 2015.05.18


Cancer is basically a class of disorder marked by uncontrolled proliferation of cells which have the potential to interfere with different systems of body like digestive, central nervous and circulatory systems by releasing hormones. Tumors that reside only in a specified location and show restricted growth are commonly characterized as benign tumors. When tumor cells grow and effectively spread to other body parts and potentially invade and damage healthy tissues they show various degrees of malignancy. Cancer may be caused by different factors like gene mutations, carcinogens and some medical factors that harm the immune system of the body. Symptoms of cancer are relatively varied and classified according to location, progression pattern and size of tumors as well. Different diagnostic tests are used for evaluation that depends on the type of cancer. Cancer management and chemo protocols also depend on the progression and site where it develops. Cancers like breast, lung, liver, colorectal, prostate, head and neck carcinoma are most commonly diagnosed in Pakistan. This review briefly describes the three most common cancers prevailing in Pakistan and their management evaluation.


  1. Watson J (2013). Oxidants, antioxidants and the current incurability of metastatic cancers. Open Biol, 3, 120144.
  2. Wilke H, Glynne-Jones R, Thaler J, et al (2008). Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL Study. J Clin Oncol, 26, 5335-43.
  3. Winton T, Livingston R, Johnson D, et al (2005). Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. New Engl J Med, 352, 2589-97.
  4. Wolin K, Yan Y, Colditz G, et al (2009). Physical activity and colon cancer prevention: a meta-analysis. Br J Cancer, 100, 611-6.
  5. Xu C-Y, Jiang Z-N, Zhou Y, et al (2013). Estrogen receptor ${\alpha}$ roles in breast cancer chemoresistance. Asian Pac J Cancer Prev, 14, 4049.
  6. Xu H-X, Huang X-E, Qian Z-Y, et al (2011). Clinical observation of Endostar$^{(R)}$ combined with chemotherapy in advanced colorectal cancer patients. Asian Pac J Cancer Prev, 12, 3087-90.
  7. Yager JD, Davidson NE (2006). Estrogen carcinogenesis in breast cancer. New Engl J Med, 354, 270-82.
  8. Yang Y, Zhang X, Yang M, et al (2014). Prognostic role of nucleophosmin in colorectal carcinomas. Asian Pac J Cancer Prev, 15, 2021-6.
  9. Zatloukal P, Petruzelka L, Zemanova M, et al (2003). Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial. Lung Cancer, 41, 321-31.
  10. Zauber AG, Winawer SJ, O'Brien MJ, et al (2012). Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. New Engl J Med, 366, 687-96.
  11. Zhang H-Q, Lian C-H, Ping Y-D, et al (2014). Pemetrexed is mildly active with good tolerability for treatment of patients with colorectal cancer. Asian Pac J Cancer Prev, 15, 8391-4.
  12. Waris G, Ahsan H (2006). Reactive oxygen species: role in the development of cancer and various chronic conditions. J Carcinogen, 5, 14.
  13. Wasserman E, Myara A, Lokiec F, et al (1997). Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports. Ann Oncol, 8, 1049-51.
  14. Siegel R, DeSantis C, Virgo K, et al (2012). Cancer treatment and survivorship statistics, 2012. Ca Cancer J Clin, 62, 220-41.
  15. Siegel R, Naishadham D, Jemal A (2013). Cancer statistics, 2013. Ca Cancer J Clin, 63, 11-30.
  16. Sohail S, Alam SN (2007). Breast cancer in pakistan-awareness and early detection. J College Physicians Surgeons Pakistan, 17, 711-2.
  17. Soong D, Hag R ,Leung M (2009). High rate of febrile neutropenia in patients with operable breast cancer receiving docetaxel and cyclophosphamide. J Clin Oncol, 27, 101-2.
  18. Sparano J, Wang M, Martino S, et al (2007). Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in operable breast cancer: results of Intergroup Trial E1199. J Clin Oncol, 25, 516.
  19. Stapel J, Oppermann C, Richter D, et al (2013). Polyphenol compounds with anti-carcinogenic qualities: Effects of quercetin (flavonol), chrysin (flavon), kaempferol (flavanol), naringenin (flavanon) and hesperidin (flavanoid) on in vitro breast cancer. J Med Plants Res, 7, 2187-96.
  20. Suganya J, Radha M, Naorem DL, et al (2014). In Silico Docking Studies of Selected flavonoids-Natural Healing Agents against Breast Cancer. Asian Pac J Cancer Prev, 15, 8155-9.
  21. Thomas C, Gustafsson J-A (2011). The different roles of ER subtypes in cancer biology and therapy. Nature Rev Cancer, 11, 597-608.
  22. Toniti W, Suthiyotha N, Puchadapirom P, et al (2011). Binding capacity of ER-alpha ligands and SERMs: comparison of the human, dog and cat. Asian Pac J Cancer Prev, 12, 2875-9.
  23. Tunio MA, Rafi M, Hashmi A, et al (2010). High-dose-rate intraluminal brachytherapy during preoperative chemoradiation for locally advanced rectal cancers. World J Gastroenterol, 16, 4436.
  24. Uncu D, Aksoy S, Cetin B, et al (2013). Results of adjuvant FOLFOX regimens in stage III colorectal cancer patients: retrospective analysis of 667 patients. Oncol, 84, 240-5.
  25. Valko M, Leibfritz D, Moncol J, et al (2007). Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell B, 39, 44-84.
  26. Van Cutsem E, Peeters M, Siena S, et al (2007). Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol, 25, 1658-64.
  27. Van Moorsel CJ, Peters GJ, Pinedo HM (1997). Gemcitabine: future prospects of single-agent and combination studies. The Oncologist, 2, 127-34.
  28. Vandenberg T, Younus J, Al-Khayyat S (2010). Febrile neutropenia rates with adjuvant docetaxel and cyclophosphamide chemotherapy in early breast cancer: discrepancy between published reports and community practice-a retrospective analysis. Curr Oncol, 17, 2-3.
  29. Verma S, Miles D, Gianni L, et al (2012). Trastuzumab emtansine for HER2-positive advanced breast cancer. New Engl J Med, 367, 1783-91.
  30. Peters WA, Liu P, Barrett RJ, et al (2000). Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol, 18, 1606-13.
  31. Rosell R, Gomez-Codina J, Camps C, et al (1999). Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial. Lung Cancer, 26, 7-14.
  32. Rosell R, Gomez-Codina J, Camps C, et al (1994). A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. New Engl J Med, 330, 153-8.
  33. Roth J, Fossella F ,Komaki R (1994). A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst, 86, 673-80.
  34. Roth JA, Atkinson EN, Fossella F, et al (1998). Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer, 21, 1-6.
  35. Rougier P, Van Cutsem E, Bajetta E, et al (1998). Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. The Lancet, 352, 1407-12.
  36. Saltz LB, Cox JV, Blanke C, et al (2000). Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. New Engl J Med, 343, 905-14.
  37. Sariego J (2010). Breast cancer in the young patient. Am Surgeon, 76, 1397-401.
  38. Scagliotti G, De Marinis F, Rinaldi M, et al (2002). Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol, 20, 4285-91.
  39. Scheithauer W, McKendrick J, Begbie S, et al (2003). Oral capecitabine as an alternative to iv 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol, 14, 1735-43.
  40. Schiller JH, Harrington D, Belani CP, et al (2002). Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. New Engl J Med, 346, 92-8.
  41. Schoen RE, Pinsky PF, Weissfeld JL, et al (2012). Colorectalcancer incidence and mortality with screening flexible sigmoidoscopy. New Engl J Med, 366, 2345-57.
  42. Schreck R, Albermann K, Baeuerle PA (1992). Nuclear factor kB: an oxidative stress-responsive transcription factor of eukaryotic cells (a review). Free Radical Res, 17, 221-37.
  43. Shepherd FA, Dancey J, Ramlau R, et al (2000). Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol, 18, 2095-103.
  44. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al (2005). Erlotinib in previously treated non-small-cell lung cancer. New Engl J Med, 353, 123-32.
  45. Mancini M, Anderson BO, Caldwell E, et al (1997). Mitochondrial proliferation and paradoxical membrane depolarization during terminal differentiation and apoptosis in a human colon carcinoma cell line. J Cell Biol, 138, 449-69
  46. Martin-Martorell P, Rosello S, Rodriguez-Braun E, et al (2008). Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a phase II single institution trial. Br J Cancer, 99, 455-8.
  47. Matakidou A, Eisen T, Houlston R (2005). Systematic review of the relationship between family history and lung cancer risk. Br J Cancer, 93, 825-33.
  48. McPherson K, Steel C, Dixon J (2000). ABC of breast diseases: breast cancer-epidemiology, risk factors, and genetics. BMJ: Br Med J, 321, 624-8.
  49. Melosky B, Burkes R, Rayson D, et al (2009). Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations. Curr Oncol, 16, 14-24.
  50. Mimi CY ,Yuan J-M (2004). Environmental factors and risk for hepatocellular carcinoma. Gastroenterol, 127, 72-S8.
  51. Montesano R, Hall J (2001). Environmental causes of human cancers. Eur J Cancer, 37, 67-87.
  52. Morikawa T, Kuchiba A, Liao X, et al (2012). Tumor TP53 expression status, body mass index and prognosis in colorectal cancer. Int J Cancer, 131, 1169-78.
  53. Murray N, Coy P, Pater JL, et al (1993). Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol, 11, 336-44.
  54. Naeem M, Khan N, Aman Z, et al (2008). Pattern of breast cancer: experience at lady reading hospital, peshawar. J Ayub Med Coll Abbottabad, 20, 22-5.
  55. Nakatsumi H, Komatsu Y, Yuki S, et al (2013). Optimal dose period for indisetron tablets for preventing chemotherapy-induced nausea and vomiting with modified FOLFOX6: A randomized pilot study. Chemother, 58, 439-44.
  56. Parkin DM (2006). The global health burden of infection-associated cancers in the year 2002. Int J Cancer, 118, 3030-44.
  57. Perez EA, Rodeheffer R (2004). Clinical cardiac tolerability of trastuzumab. J Clin Oncol, 22, 322-9.
  58. Pfeiffer P, Nielsen D, Bjerregaard J, et al (2008). Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil. Ann of Oncol, 19, 1141-5.
  59. Pieterman RM, van Putten JW, Meuzelaar JJ, et al (2000). Preoperative staging of non-small-cell lung cancer with positron-emission tomography. New Engl J Med, 343, 254-61.
  60. Pietras RJ, Pegram MD, finn RS, et al (1998). Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncog, 17, 2235-49.
  61. Khan N, Afroz F, Lone M, et al (2006). Profile of lung cancer in Kashmir, India: a five-year study. Indian J Chest Dis Allied S, 48, 187-90.
  62. Krop IE, LoRusso P, Miller KD, et al (2012). A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol, 30, 3234-41.
  63. Kuebler JP, Wieand HS, O'Connell MJ, et al (2007). Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol, 25, 2198-204.
  64. Kumar P, Bolshette NB, Jamdade VS, et al (2013). Breast cancer status in India: An overview. Biomed Prev Nutr, 3, 177-83.
  65. Lad T, Rubinstein L, Sadeghi A (1988). The benefit of adjuvant treatment for resected locally advanced non-small-cell lung-cancer. J Clin Oncol, 6, 9-17.
  66. Larsson SC, Orsini N, Wolk A (2005). Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst, 97, 1679-87.
  67. Leber MF, Efferth T (2009). Molecular principles of cancer invasion and metastasis. Int J Oncol, 34, 881-95.
  68. Levin B, Lieberman DA, McFarland B, et al (2008). Screening and Surveillance for the Early Detection of Colorectal Cancer and Adenomatous Polyps, 2008: A Joint Guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Ca Cancer J Clin, 58, 130-60.
  69. Levine M, Bramwell V, Pritchard K (1998). Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. J Clin Oncol, 16, 2651-8.
  70. Li H-Y, Zhang Y, Cai J-H, et al (2013). MicroRNA-451 inhibits growth of human colorectal carcinoma cells via downregulation of Pi3k/Akt pathway. Asian Pac J Cancer Prev, 14, 3631-4.
  71. Li X, Hemminki K (2004). Inherited predisposition to early onset lung cancer according to histological type. Int J Cancer, 112, 451-7.
  72. Liao X, Lochhead P, Nishihara R, et al (2012). Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. New Engl J Med, 367, 1596-606.
  73. Liu W-J, Tan X-H, Guo B-P, et al (2013). Associations between RASSF1A promoter methylation and NSCLC: a metaanalysis of published data. Asian Pac J Cancer Prev, 14, 3719-24.
  74. Livingston R, Moore T, Heilbrun L, et al (1978). Small-cell carcinoma of the lung: combined chemotherapy and radiation: a southwest oncology group study. Ann Intern Med, 88, 194-9.
  75. Lokich JJ, Ahlgren JD, Gullo JJ, et al (1989). A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J Clin Oncol, 7, 425-32.
  76. Hoff PM, Ansari R, Batist G, et al (2001). Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol, 19, 2282-92.
  77. Holmes EC, Gail M (1986). Surgical adjuvant therapy for stage II and stage III adenocarcinoma and large-cell undifferentiated carcinoma. J Clin Oncol, 4, 710-5.
  78. Huber MA, Kraut N, Beug H (2005). Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol, 17, 548-58.
  79. Hutchins LF, Green SJ, Ravdin PM, et al (2005). Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102. J Clin Oncol, 23, 8313-21.
  80. Huxley RR, Ansary-Moghaddam A, Clifton P, et al (2009). The impact of dietary and lifestyle risk factors on risk of colorectal cancer: a quantitative overview of the epidemiological evidence. Int J Cancer, 125, 171-80.
  81. Imamura Y, Morikawa T, Liao X, et al (2012). Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers. Clin Canc Res, 18, 4753-63.
  82. Izadi P, Mehrdad N, Foruzandeh F, et al (2012). Association of poor prognosis subtypes of breast cancer with estrogen receptor alpha methylation in Iranian women. Asian Pac J Cancer Prev, 13, 4113-7.
  83. Jarzabek K, Koda M, Kozlowski L, et al (2009). The significance of the expression of ERR${\alpha}$ as a potential biomarker in breast cancer. J Steroid Biochem, 113, 127-33.
  84. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. Ca Cancer J Clin, 61, 69-90.
  85. Jemal A, Center MM, DeSantis C, et al (2010). Global patterns of cancer incidence and mortality rates and trends. Cancer Epidem Biomar, 19, 1893-907.
  86. Jemal A, Siegel R, Ward E, et al (2009). Cancer statistics, 2009. Ca Cancer J Clin, 59, 225-49.
  87. Jones S, Holmes FA, O'Shaughnessy J, et al (2009). Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol, 27, 1177-83.
  88. Karaca H, Deniz K, Berk V, et al (2012). Association of human epidermal growth factor receptor-2 expression and clinicopathological findings in patients with colorectal cancer. Asian Pac J Cancer Prev, 13, 6221-5.
  89. Keller S, Vangel M, Adak S, et al (2000). A randomized trial of postoperative adju-vant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. N Engl J Med, 343, 1217-22.
  90. Kelloff GJ, Schilsky RL, Alberts DS, et al (2004). Colorectal adenomas a prototype for the use of surrogate end points in the development of cancer prevention drugs. Clin Cancer Res, 10, 3908-18.
  91. Ferber M, Montoya D, Yu C, et al (2003). Integrations of the hepatitis B virus (HBV) and human papillomavirus (HPV) into the human telomerase reverse transcriptase (hTERT) gene in liver and cervical cancers. Oncogene, 22, 3813-20.
  92. Ferlay J, Shin HR, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917.
  93. Firestein R, Shima K, Nosho K, et al (2010). CDK8 expression in 470 colorectal cancers in relation to ${\beta}$-catenin activation, other molecular alterations and patient survival. Int J Cancer, 126, 2863-73.
  94. Fisher B, Brown AM, Dimitrov NV, et al (1990). Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifennonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol, 8, 1483-96.
  95. Fossella F (2001). Docetaxel+Cisplatin (DC) and Docetaxel +Carboplatin (DCCb) vs Vinorelbine+Cisplatin (VC) in chemotherapy -naive patients with advanced and metastatic non-small cell lung cancer (NSCLC): Results of a multicenter, randomized phase III study. Eur J Cancer, 37, 154.
  96. Fossella F, Pereira JR, von Pawel J, et al (2003). Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: The TAX 326 study group. J Clin Oncol, 21, 3016-24.
  97. Fuqua SA (2001). The role of estrogen receptors in breast cancer metastasis. J Mammary Gland Biol, 6, 407-17.
  98. Ge Y-Z, Xu L-W, Jia R-P, et al (2014). The association between RASSF1A promoter methylation and prostate cancer: evidence from 19 published studies. Tumor Biol, 35, 3881-90.
  99. Gibson RJ, Keefe DM, Lalla RV, et al (2013). Systematic review of agents for the management of gastrointestinal mucositis in cancer patients. Support Care Cancer, 21, 313-26.
  100. Gotzsche P, Nielsen M (2011). Screening for breast cancer with mammography. Cochrane Database Syst Rev, 1, 1877.
  101. Gutman M, Couillard S, Roy J, et al (2002). Comparison of the effects of EM-652 (SCH57068), tamoxifen, toremifene, droloxifene, idoxifene, GW-5638 and raloxifene on the growth of human ZR-75-1 breast tumors in nude mice. Int J Cancer, 99, 273-8.
  102. Halliwell B (1994). Free radicals, antioxidants, and human disease: curiosity, cause, or consequence? The Lancet, 344, 721-4.
  103. Hamedeyazdan S, Fathiazad F, Sharifi S, et al (2012). Antiproliferative activity of Marrubium persicum extract in the MCF-7 human breast cancer cell line. Asian Pac J Cancer Prev, 13, 5843-8.
  104. Hashibe M, Brennan P, Chuang S-c, et al (2009). Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Cancer Epidem Biomar, 18, 541-50.
  105. Comeau J, Labruzzo MB (2012). From bench to bedside: promising colon cancer clinical trials. Am J Manag C, 19, SP32-7.
  106. Cross AJ, Ferrucci LM, Risch A, et al (2010). A large prospective study of meat consumption and colorectal cancer risk: an investigation of potential mechanisms underlying this association. Cancer Res, 70, 2406-14.
  107. Cunningham D, Humblet Y, Siena S, et al (2004). Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. New Engl J Med, 351, 337-45.
  108. Cunningham D, Pyrhonen S, James RD, et al (1998). Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. The Lancet, 352, 1413-8.
  109. Curran W, Scott C, Langer C, et al (2003). Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III NSCLC: RTOG 9410. Proc Am Soc Clin Oncol, 22, 621.
  110. Danaei G, Ding EL, Mozaffarian D, et al (2009). The preventable causes of death in the United States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors. PLoS Med, 6, 1000058.
  111. Dawood S, Broglio K, Buzdar AU, et al (2010). Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol, 28, 92-8.
  112. Dillman RO, Herndon J, Seagren SL, et al (1996). Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst, 88, 1210-5.
  113. Dillman RO, Seagren SL, Propert KJ, et al (1990). A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med, 323, 940-5.
  114. Douillard J, Cunningham D, Roth A, et al (2000). Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. The Lancet, 355, 1041-7.
  115. Edge SB, Compton CC (2010). The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol, 17, 1471-4.
  116. Ezzati M, Henley SJ, Lopez AD, et al (2005). Role of smoking in global and regional cancer epidemiology: current patterns and data needs. Int J Cancer, 116, 963-71.
  117. Ezzati M, Lopez AD (2003). Estimates of global mortality attributable to smoking in 2000. The Lancet, 362, 847-52.
  118. Fakih M (2008). Management of anti-EGFR-targeting monoclonal antibody-induced hypomagnesemia. Oncol, 22, 74-6.
  119. Fang W-J, Zheng Y, Wu L-M, et al (2012). Genome-wide analysis of aberrant DNA methylation for identification of potential biomarkers in colorectal cancer patients. Asian Pac J cancer Prev, 13, 1917-21.
  120. Andrew NF, Binbing Y, HG M (2011). Beneft/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older. J Clin Oncol, 29, 2327-33.
  121. Ariazi EA, Ariazi JL, Cordera F, et al (2006). Estrogen receptors as therapeutic targets in breast cancer. Current topics in med chem, 6, 181-202.
  122. Asif HM, Sultana S, Akhtar N, et al (2014). Prevalence, risk factors and disease knowledge of breast cancer in Pakistan. Asian Pac J Cancer Prev, 15, 4411.
  123. Badar F, Faruqui Z, Uddin N, et al (2011). Management of breast lesions by breast physicians in a heavily populated South Asian developing country. Asian Pac J Cancer Prev, 12, 827-32.
  124. Bajetta E, Di Bartolomeo M, Mariani L, et al (2004). Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. Cancer, 100, 279-87.
  125. Baselga J, Norton L, Albanell J, et al (1998). Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res, 58, 2825-31.
  126. Beck K, Thompson RL, Allen K, et al (2010). Policies and actions for cancer prevention: food, nutrition and physical activity. Open Obes J, 2, 81-94.
  127. Behera D, Balamugesh T (2004). Lung cancer in India. Indian J Chest Dis Allied Sci, 46, 269-81.
  128. Benson JR, Jatoi I (2012). The global breast cancer burden. Future Oncol, 8, 697-702.
  129. Bhurgri Y, Bhurgri A, Hassan SH, et al (2000). Cancer incidence in Karachi, Pakistan: first results from Karachi cancer registry. Int J Cancer, 85, 325-9.<325::AID-IJC5>3.0.CO;2-J
  130. Bhurgri Y, Bhurgri A, Nishter S, et al (2006a). Pakistan-country profile of cancer and cancer control 1995-2004. J Pak Med Assoc, 56, 124.
  131. Bhurgri Y, Bhurgri A, Usman A, et al (2006b). Pathoepidemiology of lung cancer in Karachi (1995-2002). Asian Pac J Cancer Prev, 7, 60.
  132. Boige V, Mendiboure J, Pignon J-P, et al (2010). Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLfiRI: FFCD 2000-05. J Clin Oncol, 28, 2556-64.
  133. Anderson BO, Cazap E, El Saghir NS, et al (2011). Optimisation of breast cancer management in low-resource and middleresource countries: executive summary of the Breast Health Global Initiative consensus, 2010. Lancet Oncol, 12, 387-98.
  134. Andre T, Boni C, Mounedji-Boudiaf L, et al (2004). Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. New Engl J Med, 350, 2343-51.
  135. Bray F, Ren JS, Masuyer E, et al (2013). Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer, 132, 1133-45.
  136. Brescia FJ, Fontenot MRG, Johnson DH, et al (1997). Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. J Clin Oncol, 15, 2996-3018.
  137. Brody JG, Rudel RA, Michels KB, et al (2007). Environmental pollutants, diet, physical activity, body size, and breast cancer: where do we stand in research to identify opportunities for prevention? Cancer, 109, 2627-34.
  138. Burris HA, Rugo HS, Vukelja SJ, et al (2011). Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol, 29, 398-405.
  139. Byers T, Perry G (1992). Dietary carotenes, vitamin C, and vitamin E as protective antioxidants in human cancers. Annu Rev Nutr, 12, 139-59.
  140. Campbell PT, Deka A, Jacobs EJ, et al (2010). Prospective study reveals associations between colorectal cancer and type 2 diabetes mellitus or insulin use in men. Gastroenterol, 139, 1138-46.
  141. Cavalli F (1998). Rare syndromes in Hodgkin's disease. Ann Oncol, 9, S109-S13.
  142. Cerutti PA (1994). Oxy-radicals and cancer. The Lancet, 344, 862-3.
  143. Chan A, Fu WH, Shih V, et al (2011). Impact of colony-stimulating factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy. Support Care Cancer, 19, 497-504.
  144. Chan AT, Baba Y, Shima K, et al (2010). Cathepsin B expression and survival in colon cancer: implications for molecular detection of neoplasia. Cancer Epidem Biomar, 19, 2777-85.
  145. Chan AT, Giovannucci EL (2010). Primary prevention of colorectal cancer. Gastroenterol, 138, 2029-43.
  146. Chao A, Thun MJ, Connell CJ, et al (2005). Meat consumption and risk of colorectal cancer. Jama, 293, 172-82.
  147. Chen Q, Xia H-W, Ge X-J, et al (2013). Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases. Asian Pac J Cancer Prev, 14, 7421-6.
  148. Chiu J, Tang V, Leung R, et al (2013). Efficacy and Tolerability of Adjuvant Oral Capecitabine plus Intravenous Oxaliplatin (XELOX) in Asian Patients with Colorectal Cancer: 4-Year Analysis. Asian Pac J cancer Prev, 14, 6585-90.
  149. Cho E, Smith-Warner SA, Spiegelman D, et al (2004). Dairy foods, calcium, and colorectal cancer: a pooled analysis of 10 cohort studies. J Natl Cancer I, 96, 1015-22.
  150. Citron ML, Berry DA, Cirrincione C, et al (2003). Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol, 21, 1431-9.
  151. Colussi D, Brandi G, Bazzoli F, et al (2013). Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention. Int J Mol Sci, 14, 16365-85.

Cited by

  1. Breast cancer risk associated with genes encoding DNA repair MRN complex: a study from Punjab, Pakistan vol.25, pp.3, 2018,